docetaxel anhydrous has been researched along with bromotetrandrine in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (bromotetrandrine) | Trials (bromotetrandrine) | Recent Studies (post-2010) (bromotetrandrine) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 22 | 1 | 9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, LM; Dai, CL; Fu, LW; Liang, YJ; Su, XD; Tao, LY; Wang, FP; Yan, YY; Zhang, X | 1 |
1 other study(ies) available for docetaxel anhydrous and bromotetrandrine
| Article | Year |
|---|---|
Reversal of P-gp-mediated multidrug resistance by Bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinolines; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Flow Cytometry; Humans; KB Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Taxoids; Vincristine; Xenograft Model Antitumor Assays | 2009 |